Nuvation Bio Inc. (NUVB)
After hours:
| Previous close | 2.5800 |
| Open | 2.5800 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 800 |
| Day's range | 2.5100 - 2.7700 |
| 52-week range | 0.9500 - 4.1600 |
| Volume | |
| Avg. volume | 1,302,732 |
| Market cap | 641.399M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.90 |
Business WireNuvation Bio Completes Acquisition of AnHeart Therapeutics
NEW YORK, April 10, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. With the acquisition’s completion, AnHeart is now a wholly-owned subsidiary of N
Business WireNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
NEW YORK, March 28, 2024--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access.
Business WireNuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
NEW YORK, March 25, 2024--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, and AnHeart Therapeutics Ltd. (AnHeart), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced that the companies have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction (the
